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Abstract
The hepatitis C virus is a blood-borne virus with a direct cytopathic action. Chronic hepa-
titis C is a prevalent and costly disease. Studies have shown that it is a significant overlap 
between hepatitis C virus and mental disorders and that a substantial number of patients 
infected are suffering from mood disturbances and neurocognitive impairment. Recently, 
the neurocognitive impairments (attention, memory, and executive function alterations) 
were recognized as being independent of liver fibrosis and representing the direct effect 
of hepatitis C virus on neurons. However, until now impairments in neurocognition are 
not associated with viral replication or overall viral burden. Moreover, interferon alpha 
is still used to treat patients with hepatitis C. According to various researchers, 30–70% 
will develop significant psychiatric symptoms, leading to a premature discontinuation 
of therapy or noncompliance and worsening of quality of life. Several potential mecha-
nisms may be implicated in the onset of a depressive episode following interferon alpha, 
the most important being the activation of immune-inflammatory pathways. This chap-
ter will present the complex and striking relationships between hepatitis C virus infec-
tion and central nervous system symptoms. A variety of approaches, which integrate the 
extensive research data (including molecular, brain imaging, and neuropsychological 
findings), will be discussed.
Keywords: hepatitis C, cognitive impairments, psychiatry
1. Introduction
Hepatitis C virus (HCV) infects about 200 million people and is considered a public problem 
worldwide. Studies suggest that patients with HCV have a high burden of comorbidities such 
as psychiatric disorders, co-infection with hepatitis B and human immunodeficiency virus 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
(HIV), atherosclerosis, chronic kidney disease, mixed cryoglobulinemia, insulin resistance, 
and several cardiovascular diseases [1, 2]. The extrahepatic manifestation is secondary to 
HCV-related inflammatory responses and autoimmune reactions. According to a recent meta-
analysis, the most frequent extrahepatic manifestation occurring in HCV-infected persons is 
depression, irrespective of alcohol and drug abuse or antiviral treatment [3].
The issue of a direct relationship between hepatitis C virus (HCV) infection and neuropsychiat-
ric symptoms was raised for some years. Initially, the psychiatric and neurocognitive complaints 
were considered as the results of impairments in liver function. About 50% of the patients com-
plain of chronic fatigue, deficits in attention, memory, learning, and depression [4–8].
Meanwhile, it has been shown that the reduction of global health-related quality of life 
(HRQoL) and development of psychiatric and neurocognitive impairments are not correlated 
with the level of hepatic alterations [9, 10].
Data point to an increasing evidence to support central nervous system (CNS) change in HCV 
patients. Several studies detected HCV in cerebrospinal fluid and brain. Further evidence was 
provided by studies using imaging techniques like magnetic resonance spectroscopy (MRS), 
positron emission tomography (PET), and single photon emission computed tomography 
(SPECT).
The mechanisms through which HCV entries and replicates in the brain are not fully eluci-
dated yet, but evidences point to microstructural changes, and cerebral metabolite abnormali-
ties [11–13].
Historically, the treatment of hepatitis C with interferon (IFN) was burdensome, compli-
cated, and often was associated with neurocognitive abnormalities, depression, anxiety, and 
psychosis.
This chapter aims to analyze the current data about the relation between chronic HCV infec-
tion, depression, and neurocognitive impairments. Also, the effects of pharmacologic viral 
clearance on cognitive dysfunction and psychiatric features will be discussed.
2. Neurocognitive impairments and hepatitis C virus
The evidence of CNS infection is supported by the detection of replicative intermediate 
forms of HCV RNA and viral proteins within the CNS. Additional mechanisms, involved in 
neurological dysfunction, are possibly related to the consequence of circulating inflamma-
tory cytokines and chemokines in the brain tissues through altered sites of the blood–brain 
barrier [14–17]. HCV ribonucleic acid (RNA) has been detected in peripheral blood mono-
nuclear cells, cerebrospinal fluid (CSF), and the brain of chronically infected patients with 
neuropathological abnormalities. The majority of reports supporting HCV in the CNS have 
used PCR-based approaches to detect viral genomes in brain tissue and CSF. The presence 
of HCV in the brain was demonstrated using immunostaining and Western blot techniques. 
The presence of RNA negative strand intermediate is considered as a direct evidence of HCV 
replication. Until now, it is not clear which cells are involved. Some authors demonstrated 
that HCV infects microglia/macrophages, astrocytes, brain microvascular endothelial cells, 
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neuroepithelioma cells, and neuroblastoma cells. More recent studies showed that CSF was 
found to be HCV positive in more than 50% of patients with HCV [18–23].
A variety of mechanisms have been hypothesized to explain the biological abnormalities in 
the brain:
a. direct infection of the brain,
b. chronic neuroinflammatory response,
c. indirect stimulation of neurotoxic cytokine pathways, and
d. toxicity mediated by vascular damage.
2.1. Neuroimaging studies
The imaging techniques that have been used to determine the biological abnormalities in 
HCV patients were: magnetic resonance spectroscopy, positron emission tomography, single 
photon computed tomography (SPECT), magnetic resonance-perfusion weighted imaging, 
and diffusion tensor imaging (DTI).
MRS provides noninvasive measures to evidence the metabolite abnormalities concentration 
in specific brain regions: myoinositol (mI), choline-containing compounds (Cho), creatine and 
phosphocreatine (Cr), glutathione, and N-acetyl aspartate (NAA). These metabolites are sen-
sitive to changes in neuronal and glial state and density.
In general, metabolites are reported as a ratio to creatine. The evidence of neuroinflam-
mation in HCV-positive patients is underlined by choline/creatine ratios. The choline-
containing compound (Cho) peak is considered a marker for cell turnover and membrane 
metabolism. They were significantly higher in the basal ganglia (BG) and white matter of 
HCV positive patients. This data was associated with elevated myoinositol/creatine ratios 
(a marker of glial density). Myoinositol is a cerebral osmolyte and considered a marker for 
gliosis. Increases are thought to reflect microglial activation and are associated with CNS 
inflammation. Choline and myoinositol were significantly higher in the BG. N-acetyl aspar-
tate (NAA) is considered a marker for neurons/axons. NAA and N-acetyl-glutamate were 
also significantly higher in BG.
Alterations in brain metabolism and neurotransmission are presented in Table 1.
In spite of the fact that the results vary greatly in the areas of the brain most affected, HCV 
positive patients with mild liver disease are characterized on MRS by higher mI (or mI/Cr), 
higher Cho (or Cho/Cr), and often lower NAA (or NAA/Cr). Those results are considered to 
represent the results of neuronal dysfunction and immune activation of microglia cells.
The main limitations of these studies are represented by:
• small study sizes,
• heterogeneity and varying selection of patients, and
• differences in data acquisition and data analysis.
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Diffusion tensor imaging (DTI) is a technique of magnetic resonance imaging that provides met-
rics for the speed and direction of water diffusion along the white matter tracts in the brain. DTI 
is a sensible method for detecting microscopic differences in tissue properties. The common DTI 
measures are mean diffusivity (MD), fractional anisotropy (FA), radial diffusivity (Dr), and axial 
diffusivity (Da). Mean diffusivity (MD) is an averaged measure of speed of diffusion in the three 
main directions. Fractional anisotropy (FA) measures the degree to which diffusion is faster in 
one direction than others. FA is used to highlight the microstructural changes, but it seems to be 
not very specific to the type of changes. Reductions in FA and elevations in MD seem to indicate 
impaired white matter integrity. Microglial state is also assessed using the positron emission 
tomography (PET) ligand PK11195, which binds to the mitochondrial membrane translocator 
protein (TPSO) present in endothelial, astroglial, and microglial cells. It is considered a marker 
for microglial activation. The most important neuroimaging findings are presented in Table 2.
2.2. Cognitive impairments
Approximately more than 50% of patients with chronic HCV infection complain of:
• poor memory,
• impaired attention, and
• fatigue.
Despite its potential clinical significance, cognitive impairments are often missed in patients 
evaluated for HCV, unless the manifestations are overt or interfere with the functionality, 
leading to impairments in health-related quality of life. When the symptomatology is very 
Author Year Technique Findings Journal
Forton et al. 2001 MRS Elevated choline/creatine (Cho/
Cr) ratio in the basal ganglia and 
frontal white matter
Lancet [24]
Forton et al. 2002 MRS Higher choline in basal ganglia, 
white matter
Hepatology [10]
Weissenborn et al 2004 MRS Decrease of the N-acetyl-aspartate 
(NAA)/Cr ratio in the frontal gray 
matter
no changes of the Cho/Cr ratio
Journal of Hepatology 
[12]
Bokemeyer et al. 2011 MRS Increased Cho and myoinositol 
concentrations in basal ganglia and 
white matter
Increased Cr, NAA, and N-acetyl-
aspartyl-glutamate in basal ganglia
Gut [25]
Nagarajan et al. 2012 Localized two-
dimensional correlated 
spectroscopy (L-COSY)
Increased myoinositol and 
glutathione
International Journal 
of Hepatology [26]
Table 1. Neuroimaging findings.
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severe, the patients could present word finding difficulties, anomia, and significant deficits 
in attention performance. In general, constructional abilities and nonverbal recall are intact in 
these patients. Many studies suggest that approximately 30% of patients with chronic HCV 
exhibit cognitive dysfunctions even in the absence of cirrhosis. It seems that the cognitive 
performances are unrelated to viral load or viral genotype. The imaging studies showed sig-
nificant reduction in striatal and midbrain dopamine availability and reduced metabolism in 
limbic, frontal, parietal, and temporal cortices. Thus, a crucial role of impaired dopaminer-
gic transmission in causing cognitive impairment in HCV-infected patients was suggested. 
Moreover, pathologic cerebral serotonin and dopamine transporter binding were observed.
Emerging lines of evidence suggest that the profile of neuropsychological dysfunction in 
HCV-infected patients is characterized by impairment in:
a. executive function,
b. sustained attention,
c. working memory, and
d. verbal learning and verbal recall.
Several cognitive impairments demonstrated in patient with HCV are presented in Table 3.
Author Year Technique Findings Journal
Bladowska 
et al.
2013 DTI Decreased FA in all white matter areas 
measured
Journal of Hepatology [27]
Thames et al. 2015 DTI Increased FA in striatum, thalamus, and 
insula
Neurology Neuroimmunology 
Neuroinflammation [28]
Grover VPB 2012 PET Significantly higher binding potential in 
all subcortical areas assessed (caudate, 
thalamus, pallidum) but in no cortical areas
Journal of Viral Hepatitis [29]
Pflugrad et al. 2016 PET No differences between patients with mild 
HCV and healthy controls
Journal of Viral Hepatitis [30]
Table 2. Neuroimaging findings in HCV patients.
Author Year Domains Journal
Weissenborn et al. 2004 Impaired executive function Journal of Hepatology [31]
Karaivazoglou et al. 2007 Impairment of verbal learning and memory Liver international [32]
Fontana et al. 2007 Impairment in verbal recall and working memory Hepatology [33]
Lowry et al. 2010 Alterations in memory, sustained attention, and 
delayed auditory recognition
Journal of Viral Hepatitis [34]
Ibrahim et al. 2016 Worse performance in nonverbal reasoning, 
attention, spatial orientation, age identification, and 
working memory
Journal of Clinical 
and Experimental 
Neuropsychology [35]
Table 3. Summary of major cognitive dysfunctions observed in patients with chronic hepatitis C virus infection.
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There is evidence that cognitive dysfunctions in HCV patients have some impact in the 
reduction of health-related quality of life, chronic fatigue, and impaired functionality. The lit-
erature demonstrates evidence of neurocognitive impairment in patients with chronic HCV 
infection. However, until now, it is not clear that these dysfunctions can be linked, wholly 
or in part, to the virus itself. The longitudinal evaluation of the cognitive functioning could 
provide valuable information regarding the persistence of symptoms after the clearance of 
virus in the periphery.
3. Depression and hepatitis C virus
Depression has long been recognized and associated with many chronic medical conditions. 
The occurrence of depression is higher in patients with chronic liver disease than that in 
the general population. The depression is a very common psychiatric comorbidity in HCV 
patients. The link between HCV and depression has been the focus of many investigations. 
Several studies have reported variability in the prevalence of depression among the HCV 
population. The prevalence of depression in HCV patients has been estimated to be 1.5–4 
times higher than in general population. Moreover, the prevalence rate seems to be unre-
lated to liver disease severity and interferon treatment. However, psychiatric comorbidities 
are usually underdiagnosed or overlooked when patients seek primary care, even though 
depression affects overall disease progression in the HCV-infected population [36–40].
Understanding the depressive disorder comorbid with HCV may be critical for developing 
effective intervention strategies. Most patients with depression will suffer noticeable changes 
in social and physical activities, a loss of interest in work or leisure activities, or poor aca-
demic performance. Another important issue is that HCV infection is often associated with 
behaviors that are condemned by society (e.g., drug use, alcoholism, and high-risk sexual 
behaviors), promoting prejudice, discrimination, and abuse against patients. Also, these mal-
adaptive behaviors could further exacerbate the depression.
The high prevalence of psychiatric comorbidities in HCV-infected patients has been typically 
associated with direct effects of the virus on the central nervous system or adverse effects 
of hepatitis C treatment. The high prevalence of psychiatric comorbidities in HCV-infected 
patients has been typically associated with direct effects of the virus on the central nervous 
system or adverse effects of hepatitis C treatment.
The comorbid depression in HCV patients could be:
a. depression that may be pre-existent,
b. a reactive depression to the diagnosis of HCV,
c. a biological effect of HCV infection, or
d. an α-interferon-induced depression.
Both biological and psychosocial factors are important considerations for the effective clinical 
management of HCV and the prevention of HCV disease progression.
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3.1. Psychosocial factors involved in development of depression
It is very important to distinguish between psychological reactions to the knowledge that one 
has been infected with HCV and the direct effects of the virus itself. Learning that one has 
contracted HCV infection represents a significant life stressor and will produce emotional 
stress in most patients, and psychiatric disorder in many. The psychological reasons for the 
development of depression are illustrated in Table 4. The psychosocial factors involved in the 
development of depression are illustrated in Table 4.
Stigma negatively affects the HRQOL, mental health, and social life of the patients, and leads 
to difficulties with receiving or accepting treatment. Poor social and work adjustment, lower 
acceptance of the illness, and higher subjective complaints are other problems associated with 
stigmatization. Researches showed that women generally are prone to experience more stig-
matization. The social stigma may cause some HCV individuals to refuse to disclose their 
HCV diagnosis. Furthermore, HCV-related stigma is an important stressor that leads to poor 
treatment adherence. In some cases, HCV-infected individuals tend to isolate themselves to 
prevent stigma-related negative attitudes. Low income is also a socio-demographic factor sig-
nificantly associated with the appearance of depressive symptoms [41–46].
The most commonly used coping styles by HCV patients are:
• problem-solving behavior,
• distraction and self-revalorization,
• religiousness and search for meaning,
• cognitive avoidance and dissimulation, and
• depressive coping.
Illness perception
Risk of cirrhosis/cancer and other health-related worries
Fear of transmitting the disease
Concerns about the complications of disease/treatment
Functional disability
Impaired quality of life
Fatigue severity
Personality disorders
Low income
Social stigma
Coping styles
Social support
Table 4. Psychosocial factors associated with the development of depression in HCV patients.
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Several studies have reported using inappropriate coping strategies in patients with HCV, 
which may negatively affect several aspects of their management.
Psychosocial interventions that include cognitive, behavioral and lifestyle strategies may 
influence the negative impact of HCV symptoms and treatment side effects on HRQOL.
3.2. Biological factors
Biological factors appear to play a significant role as well. Major depressive disorder is 
associated with the increased production of pro-inflammatory cytokines, such as interleu-
kin-1 (IL-1), IL-6, and interferon gamma (IFN-γ). Chronic HCV infection is also known to 
increase inflammatory cytokines like IL-1, IL-6, and tumor necrosis factor alpha (TNF-α). 
The inflammatory model of depression provides a possible link between the HCV infection 
and major depressive disorder. An increased macrophage migration inhibitory factor was 
also demonstrated in patients with major depression. Elevated pro-inflammatory cytokines 
have been found in patients with anxiety and depression symptoms and pharmacological 
agents who specifically inhibit inflammatory mediators seem to determine a reduction in 
depression and anxiety symptoms. The rise in cytokine levels is associated with fatigue, 
malaise, lethargy, and depression. Another effect of pro-inflammatory cytokines is the acti-
vation of the hypothalamic–pituitary–adrenal (HPA) axis, which represents the regulator 
of the stress response.
Many studies suggest that the activation of HPA pathways can modify monoamine expression 
in the CNS, and as a consequence, leading to symptoms of depression. It was demonstrated 
that the neurochemical imbalance of serotonin (5-HT), norepinephrine (NE), and dopamine 
(DA) is linked to the development of depression. Studies in HCV-infected patients demon-
strate impaired levels of dopamine and serotonin among distinct brain regions.
Many studies suggest that the activation of HPA pathways can modify monoamine expres-
sion in the CNS, and as consequence, leading to symptoms of depression. It was dem-
onstrated that the neurochemical imbalance of serotonin (5-HT), norepinephrine (NE), 
and dopamine (DA) is linked to the development of depression. Studies in HCV-infected 
patients demonstrate impaired levels of dopamine and serotonin among distinct brain 
regions [47–50].
IFN-α-induced depression may increase suicidality, impair quality of life, increase, and lead 
to noncompliance or even treatment withdrawal among patients with chronic HCV infection. 
Following IFN treatment of patients with HCV, up to 70% may develop depression. Several 
mechanisms have been proposed:
a. altered monoamine metabolism,
b. altered hypothalamus–pituitary–adrenal axis function,
c. increased rate of apoptosis, and
d. brain-derived neurotrophic factor (BDNF) reduction.
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The predictors of development of depression during antiviral treatment are:
1. history of depressive disorder,
2. sub-threshold depressive symptoms,
3. female gender,
4. low educational level, and
5. high baseline serum interleukin 6 (IL6) concentrations.
Specific risk factors for IFN-induced suicide are still unknown.
Standard treatment for CHC was for a period a combination of pegylated interferon (pegIFN) 
and ribavirin (RBV), which was known to exacerbate fatigue and depressive symptoms. 
Interferon-based regimens are related to complicated dosing schedules, weekly adminis-
tration of subcutaneous injections, and many side effects. Interferon alpha combined with 
ribavirin has been shown to be more effective than interferon alone on obtaining sustained 
virologic response. Moreover, it seems that SVR achieved with PEG-IFN-α and RBV combina-
tion therapy is durable over time [51].
Until now, we do not have sufficient data whether or not the cognitive impairments are irre-
versible in patients who have eliminated HCV after successful treatment. A study performed 
by Byrnes et al. concluded that HCV eradication was associated with an improvement in 
memory (visual and spatial) and verbal learning [52]. Another survey of 168 HCV patients 
receiving antiviral therapy with interferon and ribavirin evaluated 12 months after the ter-
mination of antiviral treatment concluded that in patients with a sustained viral response a 
significant improvement was observed in three out five cognitive domains (working memory, 
vigilance, and shared attention) [53, 54].
3.3. Direct-acting antivirals
Approval of direct-acting antivirals (DAA) against the hepatitis C virus has dramatically 
changed the management of HCV infection due to high cure rates and a favorable safety 
profile. It was reported that DAA in certain combinations are curing HCV infection in 
almost 100% of cases [55]. DAA are taken once-daily in oral combinations. Treatment dura-
tion has also been shortened considerably in comparison with interferon therapies, making 
treatment regimens more tolerable. Patient-reported outcomes (PROs) provide the patient’s 
perspective on the physical, functional, and psychological consequences of treatment and 
the degree and impact of disease symptoms. Recent regimens are interferon-free, and in 
many cases, RBV-free, and involve a combination of DAA agents. Many studies showed a 
consistent improvement in the quality of life, fatigue, and work productivity during treat-
ment in patients receiving IFN and RBV-free strategy. Newly approved oral anti-HCV 
drugs are very safe and effective, but unfortunately, they are very costly. DAAs do not seem 
to increase the neuropsychiatric risks to patients undergoing HCV triple therapy [56–60]. 
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In the absence of the neurocognitive side effects of interferon, it should be expected a sig-
nificant improvement in neurocognitive functioning if, as suggested, the impairments are 
directly attributable to HCV action on CNS.
3.4. Treatment of depression
Several studies have specifically investigated the treatment of depression in HCV patients. 
The literature suggests that depression, anxiety symptoms, and cognitive complaints are 
responsive to selective serotonin reuptake inhibitors (SSRIs) antidepressants. However, the 
neurovegetative symptoms seem to be less sensitive to SSRIs. Some evidence suggests that 
dual antidepressants neurovegetative symptoms can be better influenced with serotonin-nor-
epinephrine reuptake inhibitors (SNRIs). Although the data are not strong, it does appear that 
SSRIs might be the first choice for the treatment of interferon-induced MDD and citalopram is 
recommended as first-line treatment for IFN-induced depression. Antidepressant medication 
should be continued for at least 12 weeks following the end of IFN treatment. Antidepressant 
therapy is also indicated for those patients with baseline depressive symptoms and those with 
a history of IFN-induced depression. Data showed that antidepressant pre-treatment with 
SSRIs lowers the incidence and severity of IFN-associated depression in patients with chronic 
hepatitis C infection. But we need to keep in mind that antidepressants are not recommended 
for all HCV patients, and the indication should be tailored to each patient [54, 61–65].
4. Conclusions
HCV infection causes multiple provocations to practitioners due to nontreatment and espe-
cially treatment-related psychiatric comorbidities. The evidence reviewed in this chapter 
strongly suggests that HCV patients should be carefully monitored for psychiatric side effects 
of treatment. The psychiatric comorbidities along with the cognitive dysfunctions affect the 
patient’s care significantly and might influence the course of the disease. The mechanisms 
involved remain mainly not sufficiently understood. Psychological adjustment to illness is 
determined by a complex interaction of many factors. Psychosocial factors appear to be of sig-
nificance, particularly concerning the coping mechanisms and perceived stigma. In the long 
run, the goal is to offer a multidisciplinary approach for optimal medical and psychosocial 
management of patients with HCV.
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